Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee
Executive Summary
Next fiscal year will be a good one to redeem a voucher, and probably to qualify for one as well.
You may also be interested in...
Priority Review Voucher Fee Rises 4.6% For Fiscal 2018
As of Oct. 1, the fee for rare pediatric disease and tropical disease priority review vouchers will be $2.83m; the increase follows a slight decline in FY 2017.
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
Legislation would create a potential second priority review pathway for generics, as well as another priority review voucher program, but may not be as enticing as GDUFA II proposal.
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
Legislation would create a potential second priority review pathway for generics, as well as another priority review voucher program, but may not be as enticing as GDUFA II proposal.